Oxford Biomedica (LON:OXB) Insider Buys £102,262.50 in Stock

Oxford Biomedica plc (LON:OXB) insider Roch Doliveux bought 20,250 shares of the firm’s stock in a transaction on Wednesday, September 23rd. The shares were purchased at an average price of GBX 505 per share, for a total transaction of £102,262.50.

Oxford Biomedica Price Performance

Shares of OXB traded up GBX 11 during mid-day trading on Thursday, reaching GBX 492. The stock had a trading volume of 15,364,758 shares, compared to its average volume of 1,184,215. The firm has a market cap of £595.56 million, a price-to-earnings ratio of -18.28 and a beta of 1.09. The company has a debt-to-equity ratio of 273.08, a quick ratio of 1.67 and a current ratio of 2.21. The business has a fifty day moving average of GBX 512.48 and a 200 day moving average of GBX 576.03. Oxford Biomedica plc has a 12 month low of GBX 420 and a 12 month high of GBX 952.

Oxford Biomedica (LON:OXB) last announced its quarterly earnings data on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) EPS for the quarter. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%. Equities analysts predict that Oxford Biomedica plc will post -31.0799998 EPS for the current year.

Analyst Ratings Changes

OXB has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 595 price objective on shares of Oxford Biomedica in a report on Wednesday, September 2nd. Royal Bank Of Canada restated an “outperform” rating and set a GBX 900 target price on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 8.27 target price on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Oxford Biomedica currently has an average rating of “Moderate Buy” and an average target price of GBX 580.85.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.